Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the appointment of Dr. Brian Schwartz to its Board of Directors, effective November 15, 2020. Dr. Schwartz previously served as Chief Medical Officer at ArQule, leading its R&D until its $2.7 billion acquisition by Merck in February 2020. He expressed optimism about Enlivex’s AllocetraTM program, which is in clinical trials for sepsis and COVID-19, indicating strong potential for significant impacts on high-mortality diseases. Shai Novik, Executive Chairman, welcomed Dr. Schwartz's extensive experience in product development, which is expected to enhance shareholder value.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present its clinical development schedule for Sepsis, COVID-19, and Solid Cancer during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference on November 12, 2020. The Phase IIb trial for sepsis patients is set for Q4 2020, expecting 160 patient enrollments with interim results anticipated in Q3 2021. The ongoing COVID-19 Phase II trial will provide interim results by year-end 2020. Enlivex is also pursuing collaborations for solid cancer therapies, focusing on unmet medical needs in immune system rebalancing.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent on Allocetra™, its immunotherapy product. This patent covers treatment methods for autoimmune and inflammatory diseases like gout and Crohn’s disease. Enlivex aims to utilize Allocetra™ for life-threatening conditions with no effective treatments, including sepsis and COVID-19. CEO Oren Hershkovitz expressed optimism about Allocetra™'s potential in immune rebalancing, highlighted by preclinical data supporting its applicability.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has received authorization from the Israeli Ministry of Health to start a Phase IIb clinical trial for Allocetra™ in sepsis patients. This multi-center, placebo-controlled trial aims to enroll up to 160 patients, assessing safety, tolerability, and efficacy over 28 days. The company previously reported impressive Phase Ib results, showing zero mortality in Allocetra™-treated patients compared to 27% in controls. Allocetra™ has also been evaluated for COVID-19 treatment, with recent Phase Ib results indicating positive outcomes for five patients.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced a Key Opinion Leader webinar on November 5, 2020, focusing on COVID-19 treatment options, featuring Dr. Carlos Cordon-Cardo from Mount Sinai hospital. The session will discuss findings from over 68,000 COVID-19 patients and the potential of Allocetra™ as a treatment for severe cases. Recent Phase Ib trial results show that all five patients treated with Allocetra™ recovered. A Phase II trial is underway to further evaluate Allocetra™ in combination with standard care for 24 patients. No severe adverse events were reported.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the dosing of the first two patients in a Phase II clinical trial of Allocetra for severe and critical COVID-19 patients. This multi-center study aims to recruit up to twenty-four patients to evaluate Allocetra alongside standard care, focusing on safety, tolerability, and efficacy. The trial follows a successful Phase Ib trial where all five patients recovered. No severe adverse events were reported. The trial will observe patients for 28 days post-administration.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Israeli Ministry of Health has authorized a Phase II clinical trial for AllocetraTM targeting severe and critical COVID-19 patients. The trial aims to evaluate safety and efficacy, recruiting up to 24 patients. This follows positive results from a Phase Ib trial where all five treated patients recovered. Further details will be submitted to expedite regulatory review. The Phase Ib trial showed no severe adverse events, indicating a favorable safety profile for AllocetraTM.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive outcomes from a clinical trial of its therapy AllocetraTM on COVID-19 patients in severe/critical condition. In the trial, five patients experienced complete recovery and were discharged from the hospital after an average of 5.5 days (severe) and 8.5 days (critical). No severe adverse events were reported. Following these promising results, Enlivex plans to transition to a larger Phase II trial for COVID-19 patients, contingent upon regulatory approval. AllocetraTM could fill a treatment gap for severe COVID-19 cases.
Enlivex Therapeutics Ltd. has received a notice of allowance for a new patent in China concerning its immunotherapy product candidate, ALLOCETRA. This patent is expected to provide enhanced intellectual property protection, covering methods, uses, and pharmaceutical compositions. The patent is anticipated to be issued in Q4 2020. ALLOCETRA aims to address unmet medical needs related to organ dysfunction and acute multiple organ failure due to conditions such as Sepsis and COVID-19, in addition to treating solid tumors through immunotherapy mechanisms.
Enlivex Therapeutics (Nasdaq: ENLV) announced the publication of compelling preclinical data demonstrating a 90% reduction in mortality using its AllocetraTM treatment in a murine model of severe sepsis. The study highlights AllocetraTM's effectiveness in resolving organ failure and cytokine storms, showing significant results in a clinically relevant cecal ligation and puncture (CLP) model. This data complements previous Phase Ib clinical trial outcomes, supporting AllocetraTM's potential application in treating severe sepsis and COVID-19-related complications.
FAQ
What is the current stock price of Enlivex Therapeutics (ENLV)?
What is the market cap of Enlivex Therapeutics (ENLV)?
